REVOLUTIONIZING MEDICINE: A COMPREHENSIVE REVIEW OF MODERN DIAGNOSTIC TECHNOLOGIES
Keywords:
Keywords: Diagnostic technologies, medical imaging, molecular diagnostics, PCR, next-generation sequencing, point-of-care testing, artificial intelligence, liquid biopsy, personalized medicine, biosensors.Abstract
Abstract: Diagnostic technologies are the cornerstone of modern medicine,
enabling the accurate detection, characterization, and monitoring of human diseases.
This article provides a systematic overview of major diagnostic modalities, including
medical imaging (X-ray, computed tomography, magnetic resonance imaging,
ultrasound, and nuclear medicine), molecular diagnostics (polymerase chain reaction,
next-generation sequencing, and biosensors), point-of-care technologies, and emerging
fields such as liquid biopsy and artificial intelligence-assisted diagnosis. The article
discusses the principles, clinical applications, advantages, and limitations of each
technology. Special attention is given to the role of diagnostic technologies in early
disease detection, personalized medicine, and infectious disease outbreaks, including
the COVID-19 pandemic. The review concludes with an analysis of current
challenges—such as cost, accessibility, and data integration—and future directions,
including lab-on-a-chip devices and wearable diagnostics.
References
References
1. Bushberg, J. T., Seibert, J. A., Leidholdt, E. M., & Boone, J. M. (2012). The
essential physics of medical imaging (3rd ed.). Lippincott Williams & Wilkins. (pp.
45–48, 312–325, 478–495, 562–580, 678–702)
2. Campbell-Washburn, A. E., Ramasawmy, R., Restivo, M. C., et al. (2019).
Opportunities in interventional and diagnostic imaging using a low-field portable
MRI system. Journal of Magnetic Resonance Imaging, 50(3), 832–840. (pp. 834–
838)
3. Crowley, E., Di Nicolantonio, F., Loupakis, F., & Bardelli, A. (2013). Liquid
biopsy: Monitoring cancer-genetics in the blood. Nature Reviews Clinical
Oncology, 10(8), 472–484. (pp. 1460–1465)
4. Czernin, J., Ta, L., & Herrmann, K. (2013). Does PET/CT change the management
of cancer patients? Journal of Nuclear Medicine, 54(4), 532–540. (pp. 534–538)
5. Dunn, J., Runge, R., & Snyder, M. (2018). Wearables and the medical revolution.
Personalized Medicine, 15(5), 327–338. (pp. 328–335)
6. FDA (U.S. Food and Drug Administration). (2020). Summary of safety and
effectiveness data: FoundationOne Liquid CDx. FDA. (pp. 1–5)
7. Goodwin, S., McPherson, J. D., & McCombie, W. R. (2016). Coming of age: Ten
years of next-generation sequencing technologies. Nature Reviews Genetics, 17(6),
333–351. (pp. 190–200)
8. Kingsmore, S. F., Cakici, J. A., Dimmock, D. P., et al. (2019). Rapid whole-genome
sequencing for genetic diagnosis of critically ill infants. American Journal of
Human Genetics, 105(2), 420–433. (pp. 422–428)
9. MarketsandMarkets. (2021). Point-of-care diagnostics market by product, platform,
application, end user – global forecast to 2026. MarketsandMarkets Research. (pp.
12–18)
10. McKinney, S. M., Sieniek, M., Godbole, V., et al. (2020). International evaluation
of an AI system for breast cancer screening. Nature, 577(7788), 89–94. (pp. 90–94)
11. Mullis, K. B., & Faloona, F. A. (1987). Specific synthesis of DNA in vitro via a
polymerase-catalyzed chain reaction. Methods in Enzymology, 155, 335–350. (pp.
335–340)
12. National Lung Screening Trial Research Team. (2011). Reduced lung-cancer
mortality with low-dose computed tomographic screening. The New England
Journal of Medicine, 365(5), 395–409. (pp. 395–403)
